Clinical bottom line
Sarcopenia is increasingly recognized as a prevalent and impactful geriatric syndrome among community-dwelling older adults, contributing to functional decline, falls, and reduced quality of life. Recent advances in screening tools, including bioelectrical impedance phase angle and nomogram-based risk prediction, facilitate early identification. Nonpharmacological interventions focusing on resistance exercise and nutrition remain the cornerstone of management. Socioeconomic factors and sex differences influence sarcopenia risk and outcomes, underscoring the need for tailored, multidisciplinary approaches in community settings (Mo et al., 2022; Lai et al., 2025).
What the evidence shows
Mo et al. (2022) developed and validated a nomogram integrating clinical and demographic variables to predict sarcopenia risk in community-dwelling older adults, demonstrating good discrimination and calibration. This tool may aid clinicians in identifying high-risk individuals for targeted interventions.
Lai et al. (2025) validated phase angle cutoff values derived from bioelectrical impedance analysis (BIA) for sarcopenia screening in older Korean adults, confirming its utility as a noninvasive, rapid biomarker reflecting muscle quality and cellular integrity.
Handgrip strength remains a key functional measure; Chen et al. (2023) found that measurement method affects asymmetry detection but not weakness identification, highlighting the importance of standardized protocols.
He et al. (2026) identified circulating Tsukushi, a hepatokine, as a novel biomarker predicting incident sarcopenia and functional decline, suggesting emerging molecular targets for risk stratification.
Socioeconomic inequality is a significant determinant of probable sarcopenia, as shown by Swan et al. (2020), indicating that social determinants must be considered in prevention strategies.
Sex differences affect sarcopenia’s impact on falls risk, with Won et al. (2021) reporting greater fall risk in sarcopenic women, emphasizing the need for sex-specific assessment and interventions.
Nonpharmacological interventions, including resistance training and nutritional optimization, remain the mainstay, with ongoing research into optimal protocols (Shi et al., 2022).
Caveats and uncertainty
Most predictive models and biomarkers require external validation across diverse populations and ethnicities.
BIA-derived phase angle cutoffs may vary by device and population, limiting universal applicability.
Molecular biomarkers like Tsukushi are promising but currently lack clinical availability and require further study.
Socioeconomic and sex-related disparities complicate uniform screening and intervention strategies.
Long-term adherence and effectiveness of community-based interventions need robust evaluation.
How this may change practice
Incorporation of validated nomograms and BIA phase angle measurements can enhance early sarcopenia detection in primary care and community settings.
Awareness of socioeconomic and sex-specific risk factors should inform personalized prevention and management plans.
Multidisciplinary approaches combining physical therapy, nutrition, and social support are essential to address sarcopenia’s multifactorial nature.
Emerging biomarkers may refine risk stratification and guide future therapeutic development.
Routine sarcopenia screening may become standard in geriatric assessments, improving functional outcomes and reducing fall-related morbidity.